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WHAT IS ALREADY KNOWN ABOUT THIS TOPIC? 
• There is insufficient high quality evidence for many of the treatments of atopic eczema 
(AE), which is partly due to the heterogeneity in outcomes used in clinical trials. 
• The Harmonising Outcome Measures for Eczema (HOME) initiative defined 
“symptoms” as one of the core outcome domains that should be measured in AE clinical trials. 
WHAT DOES THIS STUDY ADD? 
•  Consensus was reached on the Patient-Oriented Eczema Measure (POEM) as the core 
instrument to measure symptoms. 
• This statement should promote awareness amongst all stakeholders.  
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SUMMARY 
Background: The Harmonising Outcome Measures for Eczema (HOME) initiative has defined 
four core outcome domains for a core outcome set (COS) to be measured in all atopic eczema 
(AE) trials to ensure cross-trial comparison: clinical signs, symptoms, quality of life and long-
term control.  
Objectives: The aim of this paper is to report on the consensus process that was used to select 
the core instrument to consistently assess symptoms in all future AE trials.  
Methods: Following the HOME roadmap, two systematic reviews were performed which 
identified three instruments that had sufficient evidence of validity, reliability, and feasibility 
to be considered for the final COS.  
Results: At the 4th international HOME meeting there was broad consensus among all 
stakeholders that the Patient-Oriented Eczema Measure (POEM) should be used as the core 
instrument (87.5% agreed, 9.4% unsure, 3.1% disagreed). 
Conclusions: All relevant stakeholders are encouraged to use POEM as the chosen instrument 
to measure the core domain of symptoms in all future AE clinical trials. Other instruments of 
interest can be used in addition to POEM. 
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INTRODUCTION 
There is insufficient high quality evidence for many of the treatments of atopic eczema (AE) 
(synonym atopic dermatitis), which is partly due to the high clinical and methodological 
heterogeneity in AE studies1. Results cannot be compared and pooled properly in systematic 
reviews (SRs) due to heterogeneity in outcomes used, hampering evidence-based clinical 
decision making. The international Harmonising Outcome Measures for Eczema (HOME) 
initiative, founded in 2010, standardizes outcome measurement in AE clinical trials by 
developing a core outcome set (COS) for AE clinical trials.2-5 A COS is defined as an agreed 
standardized set of outcomes that should be measured and reported, as a minimum, in all clinical 
trials of a specific disease or trial population.6 The use of a COS does not preclude the use of 
additional outcome measurement instruments (further referred to as ‘instruments’) of interest 
for a particular trial nor does a COS specify which instrument should be used as a primary 
outcome.  
To guide the development of a COS, HOME has developed a roadmap,7 which includes the 
Outcome Measures in Rheumatology (OMERACT) filter of Truth, Discrimination, and 
Feasibility in order to recommend core instruments 8 and the methodology of the COnsensus-
based Standards for the selection of health Measurement INstruments (COSMIN) checklist 
(cosmin.nl). It was agreed within HOME that there should be an instrument per domain, rather 
than a composite instrument covering more than one domain.  
Previously, HOME defined physician-assessed clinical signs, patient-reported symptoms, 
health-related quality of life, and long-term control as core outcome domains for AE clinical 
trials (HOME II meeting Amsterdam 2011).4 During the HOME III meeting (San Diego, 2013), 
consensus was reached that the Eczema Area and Severity Index (EASI) should be used as the 
core instrument to measure clinical signs.5, 9, 10  
The objective of the current consensus study (HOME IV, Malmö, April 2015) was to establish 
an agreement statement on the core instrument to measure the domain of patient-reported 
symptoms in AE clinical trials.  
HOME ROADMAP STEPS AND RESULTS OF THE HOME IV MEETING  
To identify and recommend an adequate instrument to measure symptoms of AE in clinical 
trials, a pre-defined process was followed as detailed in the HOME roadmap.7  
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To adequately assess symptoms of AE, the following definition of AE symptoms was 
employed11: “a departure from normal function, appearance or feeling which is noticed by a 
patient, indicating the presence of disease or abnormality”. A symptom is subjective and can 
only be measured by patients themselves.   
Stage 1: Identify instruments used to measure symptoms in AE treatment trials  
A systematic review of all AE trials published since 2000 showed that most (78%, 295/378) 
randomised controlled trials (RCTs) of AE treatments reported symptoms of AE with itch and 
sleep-loss the most frequently measured.12 However, symptoms were assessed by only 37% of 
RCTs by a stand-alone symptom measurement (visual analogue scale or numeric rating scale). 
Sixty-three percent reported symptoms as part of a composite measure (such as the SCORing 
Atopic Dermatitis (SCORAD) index, a composite instrument of clinician-rated signs and 
patient-reported symptoms) rather than a stand-alone outcome. A total of 30 composite 
instruments that included symptoms were identified, of which SCORAD was the most 
commonly used. Only 23% of RCTs reported the SCORAD symptom score separately.  
Stage 2: Establish the extent and quality of testing of the identified instruments  
A subsequent systematic review of published validation studies of instruments to measure 
symptoms of AE was performed according to COSMIN methodology.13 This review provided 
evidence of how well the instruments performed for measuring the symptoms of AE and the 
methodological quality of the validation studies. The methods and detailed results of this SR 
are published separately.14, 15  
Preliminary results included 26 eligible papers evaluating 15 different instruments for assessing 
symptoms of AE with varying degrees of validation (Table 1). 
Only three instruments had the potential to be recommended for the COS based on validation 
studies: the Itch Severity Scale (ISS), Patient-Oriented Eczema Measure (POEM) and Self-
Administered EASI (SA-EASI). The most extensively validated instrument was the POEM 
with adequate internal consistency,16 construct validity,16, 17 responsiveness16-18 and content 
validity.16 Performance of test-retest reliability16 and measurement error16, 18 remain unknown 
due to poor methodological study quality or limited evidence. Interpretation was assessed and 
demonstrated a minimal clinically important difference (MCID) of 3.4 points,18 five bands of 
severity (i.e. clear, mild, moderate, severe, very severe),19 and a mean absolute change in score 
from baseline of 7.9 (standard deviation (SD) 6.0).17 
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Stage 3 to 5: Recommendation of a core outcome instrument for the domain symptoms 
A two day consensus meeting involving 70 stakeholders (HOME IV: Malmö, Sweden, April 
23-24, 2015) was held to determine which instrument(s) could be recommended for the COS 
for the domain of symptoms.15 All conflicts of interest were disclosed to the meeting prior to 
discussions and voting. In line with previous HOME consensus meetings,4, 5 consensus was 
achieved if less than 30% of the voters disagreed. Full details of the meeting and attendees can 
be found in the published meeting report.15 
The consensus process began by agreeing which patient-reported symptoms were considered 
essential. The long-list of symptoms and discussions that led to this consensus were based on 
previously published studies,14, 20 the results of a large international survey of patients21 and 
input from patients discussions at the pre-meeting patient session and the main meeting. It was 
agreed that itch, sleep loss, dryness, red skin and irritation should be ideally included in the core 
instrument (Table 2). 
The results of the systematic reviews (Stage 1 and 2) were then considered alongside this agreed 
short-list of essential symptoms to determine which instruments were of sufficient quality and 
relevance to be considered further (Table 1). Despite performing well in validation studies, the 
Itch Severity Scale (ISS) was excluded because it only measures itch and itch-related aspects 
and therefore does not reflect the multiplicity of symptoms associated with AE. The Nottingham 
Eczema Severity Score (NESS) was also excluded as it is primarily an epidemiological tool. 
Atopic Dermatitis Quickscore (ADQ), web-based Characteristics of Itch Questionnaire (CoIQ), 
method 4 and Skin Detective Questionnaire (SDQ) lack sufficient validation studies to enable 
any meaningful assessment to be made. Instruments that demonstrated low quality in at least 
one criterion in validation studies were not considered further.  
The POEM, Patient-Oriented SCORAD (PO-SCORAD) and Self-administered EASI (SA-
EASI) were considered in detail for their suitability. PO-SCORAD was included in these further 
discussions and voting despite a lack of validation studies because it was felt important by some 
participants. After lengthy small and large group discussions, a vote was held to establish 
whether any of the instruments that had been considered in detail could be recommended as the 
core outcome instrument.   
After lengthy discussions and consideration of the evidence presented, consensus was achieved 
(87.5% agreed, 9.4% unsure) in the voting that the POEM is the most appropriate instrument 
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to measure symptoms and was therefore recommended for inclusion in the COS to measure AE 
symptoms in clinical trials.    
The PO-SCORAD and SA-EASI were not favoured, largely because it was argued that these 
instruments ask patients to perform an assessment of clinical signs ratings rather than being a 
true measurement of patient-reported symptoms.  
The POEM (http://nottingham.ac.uk/research/groups/cebd/resources/poem.aspx) is free to use 
and typically takes less than two minutes to complete. It asks about the frequency of seven 
symptoms (itch, sleep disturbance, dryness, flaking, weeping or oozing, bleeding and cracking) 
in the past seven days. However, the agreed essential symptom of redness is not included in 
POEM. In the development of this instrument, redness was deliberately excluded because of 
the difficulties in detect it in people with darker skin types 16. Additionally, POEM only captures 
the frequency of symptoms but does not measure the intensity; the relative importance of 
intensity of symptoms requires further investigation.  
The POEM generally meets the OMERACT filter of truth, discrimination and feasibility, but 
some validation gaps remain including structural validity and cross-cultural validity which is 
particularly important for global use of the instrument. These validation gaps will be addressed 
as per the HOME roadmap (Stage 4). If POEM does not perform well in these additional 
validation studies, its inclusion in the core set will be reassessed. All core outcome sets should 
evolve over time in response to new data. These validation studies are now ongoing and the 
results will be discussed at a future HOME consensus meeting.  
CONSENSUS RECOMMENDATION 
POEM is recommended as the core outcome instrument to measure symptoms of AE in all 
future clinical trials. We encourage all stakeholders, including clinicians, researchers, 
pharmaceutical industries, regulatory agencies, journal editors and insurance companies to 
acknowledge this recommendation and include POEM in all future trials in AE.  
STRENGTHS AND LIMITATIONS  
The inclusion of core outcome instruments in all future trials will reduce selective outcome 
reporting bias and facilitate comparison and pooling of study data allowing clinicians and 
patients to make better evidence-based decisions in clinical practice.  
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The HOME consensus process is an evidence-based approach with participants from several 
continents providing an international perspective at the meeting and in the wider HOME 
initiative. The inclusion of different stakeholder groups, all of whom participate on a voluntary 
basis, ensures that recommendations are widely applicable and support widespread 
dissemination and implementation. The systematic reviews investigating which instruments 
were used and the quality of these instruments provided a good evidence base and allowed the 
discussions to focus on the instruments with good measurement properties.  
The inclusion of patients is a key element of the HOME consensus process. Patients’ views are 
actively sought and have equal weight. The international survey by von Kobyletzki provided 
the opinion of a large number of patients with different skin types and ethnicities from several 
continents regarding what symptoms are important.21 Also, POEM was explicitly developed 
with patients using focus groups.16 Taken together with discussions from the pre-meeting 
patient session and active participation of patients during the main meeting, we hope the results 
of this consensus process are a good reflection of what is important to patients with regards to 
the symptoms of AE.  
Although the interdisciplinary, multi-stakeholder HOME group agreed a list of essential 
symptoms, it was clear that there is no available instrument that measures all of these. The most 
relevant stakeholders such as patient representatives, clinicians, and researchers and industry 
representatives planning, performing, and interpreting AE trials agreed to use the POEM as the 
core instrument to assess AE symptoms. However, there were no representatives from 
regulatory agencies or government funders of research at the HOME IV meeting, so greater 
efforts to engage with these stakeholder groups is required to ensure awareness and support for 
this core outcome instrument recommendation.  
FUTURE RESEARCH RECOMMENDATIONS 
Future research concerning instruments for AE symptoms should prioritise the investigation of 
the structural and cross-cultural validity of the POEM, and investigate the importance of 
intensity of symptoms in addition to the frequency of symptoms as captured using POEM. Work 
is also required to establish the role of pain/soreness in AE. Further efforts are required to ensure 
dissemination and uptake of this recommendation, and the wider HOME membership will be 
important facilitators in this regard. 
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Anyone who is interested in contributing to HOME should contact the HOME project manager 
(HOME@nottingham.ac.uk). 
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Tables 
Table 1. Recommendations of identified symptom instruments1 
Abbreviations: ADAM, Atopic Dermatitis Assessment Measure; ADQ, Atopic Dermatitis Quickscore; CoIQ, Web-based 
Characteristics of itch questionnaire; EIQ, Eppendorf Itch Questionnaire; ISS, Itch Severity Scale; LIS, Leuven Itch Scale; 
mEASI, modified Eczema Area and Severity Index; NESS, Nottingham Eczema Severity Score; POEM, Patient-Oriented 
Eczema Measure; PO-SCORAD, Patient-Oriented SCORing Atopic Dermatitis index; SA-EASI, Self-administered Eczema 
Area and Severity Index; SCORAD, SCORing Atopic Dermatitis index; SDQ, Skin Detective Questionnaire; ZRADSQ, 
Zheng-related atopic dermatitis symptom questionnaire. 
1 An update of this SR, performed after the consensus meeting, evaluated 3 additional instruments for assessing symptoms of 
AE, but these were not discussed at the consensus meeting.14   
   
Rating Instrument Recommendation 
A  - Instrument meets all required quality items and is 
recommended for use. 
B  ISS, POEM, SA-EASI Instrument meets two or more required quality items, but 
performance in all other required quality items is unclear, 
so it has the potential to be recommended in the future 
depending on the results of further validation studies. 
C  ADAM, EIQ, LIS, subjective 
SCORAD, ZRADSQ 
Instrument has low quality in at least one required quality 
criteria and is not recommended for use. 
D ADQ, CoIQ, mEASI, method 4, 
NESS, PO-SCORAD, SDQ 
Instrument has almost not been validated or the 
performance in all or most relevant quality items is 
unclear, so that it is not recommended to be used until 
further validation studies clarify its quality. 
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Table 2. Symptoms of importance to patients  
Symptoms important to patients Considered essential? 
Amount of body affected   
Bleeding   
Burning   
Cracking   
Discoloration   
Dry, flaky skin  Yes 
Fatigue   
General symptoms  
Hypersensitivity  
Involvement of "visible" or "sensitive” body sites  
Irritation Yes 
Itch Yes 
Lichenification  
Pain / soreness  
Rash  
Redness Yes 
Scratch marks   
Skin feels hot or inflamed  
Sleep loss  Yes 
Tightness   
Weeping / oozing 
 
  
